Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
IPO Year: n/a
Exchange: NASDAQ
Website: aerpio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2021 | $22.00 | Neutral → Buy | HC Wainwright & Co. |
HC Wainwright & Co. upgraded Aerpio Pharmaceuticals from Neutral to Buy and set a new price target of $22.00
HC Wainwright resumed coverage of Aerpio Pharmaceuticals with a rating of Hold
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020. As part of this process, the Company will explore strategic options for partnering its programs, as well as, the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-licens
EFFECT - Aadi Bioscience, Inc. (0001422142) (Filer)
S-8 - Aadi Bioscience, Inc. (0001422142) (Filer)
S-3 - Aadi Bioscience, Inc. (0001422142) (Filer)
8-K/A - Aadi Bioscience, Inc. (0001422142) (Filer)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
D - Aadi Bioscience, Inc. (0001422142) (Filer)
D - Aadi Bioscience, Inc. (0001422142) (Filer)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Key Business Update: On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company ("Aadi"), and Aspen Merger Subsidiary, Inc., a D
CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on develo
CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compound
Ended first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to March 31, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc. CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. Key Business Update: On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company ("Aadi"), and Aspen Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly
Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience's late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genesConcurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital Partners; BVF Partners, L.P.; Vivo Capital; Alta Bioequities, L.P.; Rock Springs Capital; RTW Investments, LP; Acorn Bioventures; and Serrado Capital LLCCombined company cash at closing will fund operations into 2024Rolling NDA submission to the FDA for FYARROTM in advanced malignant perivascular epithelioid sarcoma
Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on maximizing stockholder value from existing clinical and preclinical assets and cash resourcesAerpio discontinued RESCUE trial, prior to completion, due to challenges recruiting and monitoring COVID-19 patients in the current pandemic environmentAerpio’s participation in the I-SPY COVID trial has likewise been discontinued CINCINNATI, March 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 in indications in which
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020. As part of this process, the Company will explore strategic options for partnering its programs, as well as, the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-licens
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials CINCINNATI, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.(Aerpio) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome (“ARDS”) associated with COVID-19 infections, today announced that razuprotafib met the primary efficacy endpoint
SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aerpio Pharmaceuticals, Inc. (0001422142) (Subject)
SC 13G - Aerpio Pharmaceuticals, Inc. (0001422142) (Subject)
SC 13D - Aerpio Pharmaceuticals, Inc. (0001422142) (Subject)
SC 13G - Aerpio Pharmaceuticals, Inc. (0001422142) (Subject)